• Sequence: His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂

• Molecular Formula: C₄₇H₅₈N₁₂O₆

• Molecular Weight: ~887.0 g/mol

• Half-Life: ~60–90 minutes

• Class: Synthetic hexapeptide; Ghrelin mimetic acting on GHS-R1a receptors

• Name: Hexarelin Acetate

• Type: Synthetic GH secretagogue peptide

• Function: Stimulates a powerful, natural GH release and increases IGF-1

• Use: Applied in muscle growth, fat metabolism, injury recovery, and cardiac repair research

• Notable Feature: The strongest GH-stimulating peptide among GHRP variants

• A strong, pulsatile release of GH

• Subsequent rise in IGF-1, promoting anabolic tissue repair

• Cardioprotective effects, including reduced apoptosis in cardiac tissue

• No binding to IGF-binding proteins, allowing more bioactive IGF-1

• Minimal effect on appetite, unlike GHRP-6

• Increases muscle fiber density and hypertrophy

• Boosts strength, endurance, and muscle recovery

• Supports tendon and joint healing

• Increases basal metabolic rate (BMR)

• Enhances fat oxidation in fasting states

• Helps maintain lean mass during cutting phases

• Reduces cardiac fibrosis and apoptosis (shown in rodent models)

• Enhances cardiac output and ejection fraction

• Investigated for post-myocardial infarction repair

• Injectable (Subcutaneous) – standard for peptide therapy

• Often used alone or stacked with CJC-1295 no DAC or other GH boosters

• GH Release Potency: Hexarelin has shown the highest GH-releasing effect among all GHRPs

• IGF-1 Elevation: Significantly increases circulating IGF-1, enhancing muscle protein synthesis

• Cardiac Health: Rodent studies demonstrated reduction in heart failure symptoms and fibrotic damage

• Tissue Healing: Improved connective tissue repair and bone mineral density in preclinical models

While human trials are limited, Hexarelin's effects have been well-documented in GH-deficient and aged populations.

• Mild water retention or bloating

• Temporary numbness or tingling (GH-related)

• Slight cortisol and prolactin elevation (higher than GHRP-2 or Ipamorelin)

• Injection site irritation

• Consider monitoring fasting glucose, IGF-1, prolactin, cortisol with extended use

• Tolerance may develop over prolonged cycles—cycling is advised

• FDA Status: Not approved for human therapy

• Research Status: Available as research peptide

• WADA Status: Prohibited in competitive sports for performance enhancement